Table 2.
Prognostic factors for overall survival and disease-free survival associated with lymphovascular invasion.
| Disease Free Survival | Overall Survival | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||||||||
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | ||||||
| Age | ≥50 vs. <50 | 1.286 | 1.044 | 1.583 | 0.018 | 1.208 | 0.972 | 1.502 | 0.088 | 1.926 | 1.455 | 2.550 | <0.001 | 1.781 | 1.328 | 2.387 | <0.001 |
| T stage | ≥2 vs. 1 | 2.264 | 1.839 | 2.788 | <0.001 | 1.618 | 1.275 | 2.054 | <0.001 | 2.288 | 1.754 | 2.985 | <0.001 | 1.616 | 1.192 | 2.192 | 0.002 |
| N stage | 0 | ref | ref | ref | ref | ||||||||||||
| 1 | 1.633 | 1.271 | 2.099 | <0.001 | 1.399 | 1.034 | 1.893 | 0.029 | 1.920 | 1.407 | 2.662 | <0.001 | 1.846 | 1.268 | 2.688 | 0.001 | |
| 2–3 | 3.729 | 2.670 | 5.209 | <0.001 | 2.898 | 1.808 | 4.644 | <0.001 | 4.314 | 2.858 | 6.511 | <0.001 | 3.943 | 2.231 | 6.971 | <0.001 | |
| Histologic Grade | 1 | ref | ref | ref | ref | ||||||||||||
| 2 | 1.784 | 1.327 | 2.397 | <0.001 | 1.435 | 1.050 | 1.960 | 0.023 | 1.758 | 1.198 | 2.580 | 0.004 | 1.543 | 1.03 | 2.312 | 0.035 | |
| 3 | 2.563 | 1.869 | 3.515 | <0.001 | 1.850 | 1.256 | 2.724 | 0.002 | 2.713 | 1.812 | 4.062 | <0.001 | 2.322 | 1.42 | 3.798 | 0.001 | |
| LVI | (+) vs (-) | 2.563 | 1.966 | 3.339 | <0.001 | 1.766 | 1.301 | 2.397 | <0.001 | 2.744 | 1.973 | 3.815 | <0.001 | 1.958 | 1.344 | 2.853 | <0.001 |
| Subtype | HRs(+) HER2(-) | ref | ref | ref | ref | ||||||||||||
| HRs(+) HER2(+) | 0.994 | 0.683 | 1.446 | 0.973 | 0.871 | 0.497 | 1.528 | 0.630 | 0.748 | 0.440 | 1.273 | 0.285 | 0.448 | 0.187 | 1.075 | 0.072 | |
| HRs(-) HER2 (+) | 1.258 | 0.869 | 1.821 | 0.224 | 1.137 | 0.502 | 2.573 | 0.759 | 0.914 | 0.537 | 1.555 | 0.740 | 0.432 | 0.144 | 1.297 | 0.135 | |
| HRs(-) HER2(-) | 1.830 | 1.412 | 2.372 | <0.001 | 1.845 | 0.953 | 3.569 | 0.069 | 1.819 | 1.315 | 2.514 | <0.001 | 1.315 | 0.599 | 2.888 | 0.495 | |
| Adjuvant Chemotherapy | Yes vs. No | 1.503 | 1.214 | 1.862 | <0.001 | 0.912 | 0.692 | 1.201 | 0.510 | 1.223 | 0.942 | 1.614 | 0.127 | 0.662 | 0.468 | 0.937 | 0.02 |
| Endocrine therapy | Yes vs. No | 0.614 | 0.493 | 0.765 | <0.001 | 1.140 | 0.608 | 2.138 | 0.684 | 0.624 | 0.471 | 0.827 | 0.001 | 0.825 | 0.392 | 1.735 | 0.612 |
| Herceptin treatment | Yes vs. No | 1.032 | 0.750 | 1.420 | 0.846 | 0.843 | 0.478 | 1.486 | 0.554 | 0.849 | 0.546 | 1.320 | 0.849 | 1.287 | 0.545 | 3.039 | 0.566 |
| Radiotherapy | Yes vs. No | 0.570 | 0.464 | 0.701 | <0.001 | 0.581 | 0.387 | 0.871 | 0.009 | 0.571 | 0.438 | 0.743 | <0.001 | 0.575 | 0.352 | 0.941 | 0.028 |
| Breast surgery | TM vs. PM | 2.199 | 1.790 | 2.702 | <0.001 | 1.204 | 0.807 | 1.797 | 0.362 | 2.242 | 1.721 | 2.921 | <0.001 | 1.222 | 0.751 | 1.99 | 0.420 |
LVI, lymphovascular invasion; HRs, hormone receptor; HER2, human epidermal growth factor-2 receptor; TM, total mastectomy; PM, partial mastectomy; CI, confidence interval.